Without the efforts of this “small band of anticapitalist activists,” the authors argue, Lykos Therapeutics’ “$250 million investment” in MDMA-AT may have paid off by being the first psychedelic therapy to get federal approval – potentially establishing the company as a multibillion-dollar enterprise. As a journalist who has followed the psychedelics movement for years and attended hearings…
One thing has definitely changed, though: MDMA is no longer the main character of the Psychedelic Renaissance. Local decriminalization and legalization efforts march forward across the country, with a fast-growing underground market of products and services centered around psilocybin, but also featuring DMT, LSD, and a number of more obscure psychoactives. “I’m frustrated that MDMA…
An Elon Musk ally is seeking to seize control of psychedelic drugmaker Lykos Therapeutics, offering it a financial lifeline for its bid to garner US approval to use the party drug ecstasy as a mental health treatment. Antonio Gracias, an early Tesla backer and former board member who backed Musk’s takeover of Twitter, made a…
…the U.S. Department of Veterans Affairs announced that it will fund a study on Methylenedioxymethamphetamine-assisted, or MDMA-assisted, therapy for post-traumatic stress disorder and alcohol use disorder among Veterans. This is the first VA-funded study for psychedelic-assisted therapy since the 1960s. The study is scheduled to take place at the Providence VA Medical Center in Rhode…
The research… from Johns Hopkins University, surveyed 879 healthcare providers, shedding light on current attitudes, knowledge levels, and concerns… The vast majority of respondents, 93%, endorsed the potential of psilocybin and 76% supported the promise of MDMA in clinical settings. However, self-reported knowledge did not align with objective assessments. While participants rated their understanding of psilocybin’s…
“I’m not going to go smoke pot and hang out on my couch for the next 20 years,” he said in an interview, criticizing the agency for failing to grasp the drug’s potential to relieve suffering. Still, it has been a brutally rough stretch for Doblin and MAPS, which over decades have shepherded an illegal…
Lykos and its founder, Rick Doblin, have for years tried to persuade regulators and the pharmaceutical industry at large that psychedelic drugs should be used in the treatment of certain mental health conditions. “After 38 plus years of work, I’m profoundly saddened by the FDA decision around this critically needed therapy, but am heartened that…
The FDA declined to approve the new treatment submitted by Lykos Therapeutics, an organization that develops innovations to “transform mental healthcare,” deciding that there still isn’t enough evidence of benefit to outweigh the risks. The decision will have far-reaching ripple effects. Some psychedelic advocates will have to put celebrations they’ve been planning for decades on pause;…
By August 11 [2024], the Food and Drug Administration is expected to decide whether MDMA – the chemical found in ecstasy or molly – can be prescribed as a treatment for post-traumatic stress disorder. The downvote in June [2024] – not to mention controversy about the trials that spilled into full view during a public hearing –…
A recent survey of 3,294 US adults, aged between 42 and 92, has found that… compared to those who did not use psychedelics, those who did scored higher on tests… which assessed inductive reasoning, verbal fluency, working memory, processing speed, attention switching, and inhibitory control. Psilocybin, LSD, MDMA, and other psychedelics appear to stimulate new connections between…
Recent Comments